Abstract B114: Progesterone receptor membrane component 1 is a candidate key molecule involved EGFR-TKI resistance in lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-b114
Abstract: To overcome the resistance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer, the mechanism clarification and novel molecular target development are urgently required. From this viewpoint, we previously identified… read more here.
Keywords: treatment; resistance; tki resistance; pc9 ... See more keywords
FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF-κB Signaling Pathway in EGFR-Mutant NSCLC Cells
Sign Up to like & getrecommendations! Published in 2022 at "Marine Drugs"
DOI: 10.3390/md20010076
Abstract: FGFC1, an active compound isolated from the culture of marine fungi Stachybotrys longispora FG216, elicits fibrinolytic, anti-oxidative, and anti-inflammatory activity. We have previously reported that FGFC1 inhibited the proliferation, migration, and invasion of the non-small… read more here.
Keywords: pc9; cancer activity; anti cancer; activity ... See more keywords
Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway
Sign Up to like & getrecommendations! Published in 2017 at "Oncology Letters"
DOI: 10.3892/ol.2017.5878
Abstract: The aim of the present study was to gain insight into the molecular mechanism of gefitinib resistance in non-small cell lung cancer (NSCLC), and demonstrate whether long noncoding RNA (lncRNA) expression signatures differ between gefitinib-sensitive… read more here.
Keywords: egfr pi3k; pi3k akt; pc9; expression ... See more keywords
Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway.
Sign Up to like & getrecommendations! Published in 2017 at "Oncology reports"
DOI: 10.3892/or.2017.5938
Abstract: Epidermal growth factor receptor-targeted tyrosine kinase inhibitors (EGFR-TKIs) have become first-line drugs used for non-small cell lung cancer (NSCLC) treatment. However, drug resistance to EGFR-TKIs will be developed inevitably due to the repeated use of… read more here.
Keywords: cancer stem; cscs; pc9; lung cancer ... See more keywords